Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Fierce Pharma18h
Roche settles UPenn suit alleging patent infringement by Herceptin, 3 other breast cancer meds
Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...
Fierce Biotech3d
Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
BioSpace4d
Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit
In connection with Spark’s overhaul, Roche will incur approximately $2.4 billion in goodwill impairment costs. This sum takes ...
Fierce Pharma4d
Roche overhauls Spark gene therapy unit, recording $2.4B in full impairment
Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma ...
Roche Diagnostics supports UK eye cancer AI initiative
Roche Diagnostics is collaborating with the University of Liverpool to launch the Eye Cancer Artificial Intelligence Digital Bioresource (EYE-CAN-AID), a multi-modal image database that aims to boost ...
Medical Dialogues1d
Roche, Zealand Pharma ink pact to co-develop, co-commercialise petrelintide as foundational therapy for obesity
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.
Analytics India Magazine1d
Inside Roche’s Leadership Formula for GCC Success in India
Roche’s work in India is powered by its digital centre of excellence, which Jamalamadaka mentioned “operates as an integral ...